Merit Medical Systems (NASDAQ:MMSI – Get Free Report)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a report released on Monday, Benzinga reports. They presently have a $105.00 price target on the medical instruments supplier’s stock. Needham & Company LLC’s price target would indicate a potential upside of 6.59% from the stock’s current price.
A number of other research analysts have also recently issued reports on MMSI. StockNews.com raised Merit Medical Systems from a “hold” rating to a “buy” rating in a report on Monday, August 5th. Piper Sandler restated an “overweight” rating and set a $110.00 target price (up from $100.00) on shares of Merit Medical Systems in a research report on Monday, September 9th. Canaccord Genuity Group lifted their price objective on Merit Medical Systems from $102.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Bank of America lifted their price objective on Merit Medical Systems from $92.00 to $103.00 and gave the company a “neutral” rating in a report on Monday. Finally, Robert W. Baird initiated coverage on Merit Medical Systems in a research note on Friday, June 28th. They issued an “outperform” rating and a $96.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $100.55.
View Our Latest Report on MMSI
Merit Medical Systems Stock Down 1.1 %
Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.04. The company had revenue of $338.00 million during the quarter, compared to analysts’ expectations of $334.94 million. Merit Medical Systems had a return on equity of 15.29% and a net margin of 9.02%. As a group, equities research analysts expect that Merit Medical Systems will post 3.31 earnings per share for the current fiscal year.
Insider Transactions at Merit Medical Systems
In other news, Director F. Ann Millner sold 12,500 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $85.00, for a total transaction of $1,062,500.00. Following the sale, the director now owns 32,391 shares in the company, valued at approximately $2,753,235. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 3.70% of the company’s stock.
Institutional Investors Weigh In On Merit Medical Systems
Institutional investors and hedge funds have recently made changes to their positions in the stock. Trexquant Investment LP acquired a new position in shares of Merit Medical Systems during the 4th quarter worth approximately $2,427,000. Capstone Investment Advisors LLC acquired a new position in shares of Merit Medical Systems during the 4th quarter worth approximately $3,424,000. UniSuper Management Pty Ltd acquired a new position in shares of Merit Medical Systems during the 1st quarter worth approximately $1,083,000. Quantbot Technologies LP increased its holdings in shares of Merit Medical Systems by 17,716.1% during the 1st quarter. Quantbot Technologies LP now owns 9,977 shares of the medical instruments supplier’s stock worth $756,000 after acquiring an additional 9,921 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Merit Medical Systems by 3.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,306,702 shares of the medical instruments supplier’s stock worth $99,258,000 after acquiring an additional 41,065 shares during the last quarter. Institutional investors own 99.66% of the company’s stock.
Merit Medical Systems Company Profile
Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.
Featured Articles
- Five stocks we like better than Merit Medical Systems
- Conference Calls and Individual Investors
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- EV Stocks and How to Profit from Them
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.